Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

109.85 +2.46 (+2.29%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Kymera Therapeutics to Participate in Upcoming June Investor Conference

June 01, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

May 22, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

May 19, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics's Return On Capital Employed Insights ↗

February 27, 2023

Via Benzinga

Analyst Ratings for Kymera Therapeutics ↗

February 24, 2023

Via Benzinga

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

May 18, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

7 Growth Stocks That Could Double Your Money in 2023 ↗

May 14, 2023

For investors that really want to roll the dice, these are the enticing growth stocks that could double your money.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023 ↗

May 05, 2023

Via Benzinga

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

May 04, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

April 11, 2023

Company also presenting at upcoming investor conferences

From Kymera Therapeutics, Inc.

Via GlobeNewswire

7 Biotech Stocks to Buy for 100% Returns ↗

April 09, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

Via InvestorPlace

Join These Motley Fool Investors for "The Market Cap Game Show" ↗

April 01, 2023

Multiplying the number of shares by the share price is just step one.

Via The Motley Fool

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗

March 11, 2023

The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...

Via Benzinga

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

March 01, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

February 23, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

February 01, 2023

Company also presenting at upcoming investor conferences

From Kymera Therapeutics, Inc.

Via GlobeNewswire

X-Chem and Kymera Expand Existing Partnership

January 31, 2023

From X-Chem

Via Business Wire

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

January 10, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

January 04, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

January 03, 2023

From Kymera Therapeutics, Inc.

Via GlobeNewswire

7 Perfect Presents to Gift Your 2023 Stock Portfolio ↗

December 21, 2022

As we leave 2022 behind, these hot stocks to buy have significant potential and serious catalysts as we move into New Year 2023.

Via InvestorPlace

Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 14, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

These Biotech Stocks Are the Nasdaq's Big Wednesday Winners ↗

December 14, 2022

Business wins are shining the spotlight on these two companies.

Via The Motley Fool

Dear DS Stock Fans, Mark Your Calendars for Dec. 23 ↗

December 14, 2022

Drive Shack (DS) stock is falling hard on Wednesday after the company warned investors of it delisting shares this month.

Via InvestorPlace

Why Is SOFI Stock Up 7% Today? ↗

December 14, 2022

SoFi Technologies (SOFI) stock is climbing higher on Wednesday after the company's CEO bought over 1 million more shares.

Via InvestorPlace

Dear CRKN Stock Fans, Mark Your Calendars for Dec. 22 ↗

December 14, 2022

Crown Electrokinetics (CRKN) stock is on the move Wednesday as investors prepare for the company's upcoming shareholder meeting.

Via InvestorPlace

Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today? ↗

December 14, 2022

KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase.

Via InvestorPlace

REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗

December 14, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial ↗

December 14, 2022

Via Benzinga

US Stocks Higher Ahead Of Fed Decision ↗

December 14, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining over 80 points on Wednesday

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.